This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
News|Webcasts|October 28, 2024
Solving the Insoluble: Webinar on the Science and Application of the Dispersome® Technology
Webinar Date/Time: Tue, Nov 12, 2024 9:00 AM EST
Do you have problems with insoluble drugs or nutraceutical candidates? This new webinar highlights the use of beta-lactoglobulin as a novel excipient in Dispersome® formulations, a new solubility-enhancing technology that can improve performance and increase bioavailability.
Register Free:
Event Overview:
Poor drug solubility remains a big headache for biotech and pharma companies, resulting in severe delays or even drug development failure. Increasing drug solubility by applying the Dispersome® technology results in enhanced oral bioavailability, lower drug dosing, and better formulations. The Dispersome® technology is a new solubility-enhancing technology and is a compelling alternative to other solubility-enhancing technologies, simply because Dispersome® provide better performance with respect to solubility and bioavailability increase, even of practically insoluble drugs. The technology is based on the use of pharma-grade beta-lactoglobulin (BLG) as a novel pharmaceutical excipient, which stabilizes the drug into an amorphous and highly soluble form. This webinar will give a comprehensive overview on the science behind the Dispersome® technology and showcase different case studies for several programs in the pharmaceutical and neutraceutical space.
Key Learning Objectives
- Gain insights on the science behind solubility enhancement using the Dispersome® technology.
- Learn how the technology can be applied for developing more new drugs into commercial products and allows for improvement of existing drugs.
- Understand how the technology can be applied in the nutraceutical space.
Who Should Attend
- Pharmaceutical researchers and scientists
- Oral product development professionals
- CMC experts on oral drug delivery and formulation
- Business development, portfolio management, and technology licensing experts
Speakers
Korbinian Löbmann, PhD
Chief Scientific Officer
Zerion Pharma A/S
Emmanuel Heinrich, PhD
Fellow Scientist
Hovione
Register Free:
Related to this article
Christy Owings, Thermo Fisher, explains clinical trial supply chain risks in Latin America, importer-of-record strategy, AI, and eCOA delays.
PharmTech AI Pulse Check debuts: pharma experts tackle GxP 'slop,' multi-agent validation risk, OCR document mining, personalized mRNA cancer therapy.
Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.